Iain A M MacPhee
Overview
Explore the profile of Iain A M MacPhee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
457
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kirwan C, Philips B, MacPhee I
Crit Care Res Pract
. 2013 Mar;
2013:406075.
PMID: 23476756
Introduction. RIFLE and AKIN provide a standardised classification of acute kidney injury (AKI), but their categorical rather than continuous nature restricts their use to a research tool. A more accurate...
12.
Boughton O, Borgulya G, Cecconi M, Fredericks S, Moreton-Clack M, MacPhee I
Br J Clin Pharmacol
. 2013 Jan;
76(3):425-31.
PMID: 23305195
Aims: An algorithm based on the CYP3A5 genotype to predict tacrolimus clearance to inform the optimal initial dose was derived using data from the DeKAF study (Passey et al. Br...
13.
MacPhee I
Clin Chim Acta
. 2011 Nov;
413(17-18):1312-7.
PMID: 22037511
The immunosuppressive drugs used for solid organ transplantation all have a narrow therapeutic index with wide variation between individuals in the blood concentration achieved by a given dose. Therapeutic drug...
14.
Bouamar R, Hesselink D, van Schaik R, Weimar W, MacPhee I, De Fijter J, et al.
Ther Drug Monit
. 2011 Mar;
33(2):178-84.
PMID: 21383650
Background: The association of CYP3A5, CYP3A4, and ABCB1 single nucleotide polymorphisms (SNPs) with cyclosporine (CsA) pharmacokinetics is controversial. The authors studied the influence of these SNPs on CsA pharmacokinetics as...
15.
Ware N, MacPhee I
Curr Opin Mol Ther
. 2010 Jun;
12(3):270-83.
PMID: 20521216
The immunosuppressive drugs used in organ transplantation typically have a narrow therapeutic index, with wide variation in the blood concentration achieved from a given dose observed between individuals. This issue...
16.
MacPhee I
Ther Drug Monit
. 2010 May;
32(3):261-4.
PMID: 20431509
Pharmacogenetic strategies offer promise as an adjunct to therapeutic drug monitoring in achieving target blood concentrations of the immunosuppressive drugs as early as possible after transplantation. To date, the only...
17.
Ng F, Holt D, Chang R, MacPhee I
Nephrol Dial Transplant
. 2009 Oct;
25(2):628-34.
PMID: 19825838
Background: African American transplant recipients have poorer long-term outcomes than Caucasian Americans. This difference was not found in French patients, suggesting socialized medicine overcame this disparity. It has also been...
18.
Kirwan C, Lee T, Holt D, Grounds R, MacPhee I, Philips B
Intensive Care Med
. 2009 Feb;
35(7):1271-5.
PMID: 19198803
Objective: Critical illness and associated sequelae can cause severe metabolic disturbances. The effects these have on hepatic drug metabolism are poorly understood. In vivo, enzyme specific drug probes are used...
19.
White L, Casian A, Hilton R, MacPhee I, Marsh J, Sweny P, et al.
Transplantation
. 2008 Apr;
85(7):1008-15.
PMID: 18408582
Background: BK nephropathy (BKN) is an important cause of renal transplant dysfunction, believed to be associated with higher levels of immunosuppression. We assessed the experience of BKN in renal transplant...
20.
MacPhee I, Holt D
Transplantation
. 2008 Jan;
85(2):163-5.
PMID: 18212618
Pharmacogenetics has the potential to complement therapeutic drug monitoring in achieving target blood concentrations of the immunosuppressive drugs during the critical early period after transplantation when adequate drug exposure is...